A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8 | Ophthalmology | JAMA Ophthalmology | JAMA Network
[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
National Advisory Eye Council, Report of the Retinal Diseases Panel: Vision Research: A National Plan, 1994-1998.  Bethesda, Md United States Dept of Health and Human Services1993;Publication NIH 93-3186.
Klein  RWang  QKlein  BEKMoss  SEMeuer  SM The relationship of age-related maculopathy, cataract, and glaucoma to visual acuity.  Invest Ophthalmol Vis Sci. 1995;36182- 191Google Scholar
Attebo  KMitchell  PSmith  W Visual acuity and the causes of visual loss in Australia: the Blue Mountains Eye Study.  Ophthalmology. 1996;103357- 364Google ScholarCrossref
Klaver  CCWolfs  RCVingerling  JRHofman  AdeJong  PT Age-specific prevalence and causes of blindness and visual impairment in an older population: the Rotterdam Study.  Arch Ophthalmol. 1998;116653- 658Google ScholarCrossref
Macular Photocoagulation Study Group, Argon laser photocoagulation for neovascular maculopathy: five-year results from randomized clinical trials.  Arch Ophthalmol. 1991;1091109- 1114[published correction appears in Arch Ophthalmol. 1992;110:761].Google ScholarCrossref
Macular Photocoagulation Study Group, Laser photocoagulation for subfoveal lesions of age-related macular degeneration: updated findings from two clinical trials.  Arch Ophthalmol. 1993;1111200- 1209Google ScholarCrossref
Treatment of Age-Related Macular Degeneration With Photodynamic Therapy(TAP) Study Group, Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: two-year results of 2 randomized clinical trials: TAP Report 2.  Arch Ophthalmol. 2001;119198- 207Google Scholar
Verteporfin In Photodynamic Therapy (VIP) Study Group, Verteporfin therapy of subfoveal choroidal neovascularization in age-related macular degeneration: two-year results of a randomized clinical trial including lesions with occult with no classic choroidal neovascularization—Verteporfin in Photodynamic Therapy Report 2.  Am J Ophthalmol. 2001;131541- 560Google ScholarCrossref
Fine  SLBerger  JWMaguire  MGHo  AC Drug therapy: age-related macular degeneration.  N Engl J Med. 2000;342483- 492Google ScholarCrossref
Olk  RJFriberg  TRStickney  K  et al.  Therapeutic benefits of infrared (810 nm) diode laser macular grid photocoagulation in prophylactic treatment of non-extensive age-related macular degeneration.  Ophthalmology. 1999;1062082- 2090Google ScholarCrossref
Friberg  TR Laser photocoagulation of eyes with drusen: will it help?  Semin Ophthalmol. 1999;1445- 50Google ScholarCrossref
Choroidal Neovascularization Prevention Research Group, Laser treatment in eyes with large drusen: short term effects in a pilot randomized clinical trial.  Ophthalmology. 1998;10511- 23Google ScholarCrossref
Bressler  NM Submacular surgery: new information, more questions.  Arch Ophthalmol. 1997;1151071- 1072Google ScholarCrossref
Fliesler  SJAnderson  RE Chemistry and metabolism of lipids in the vertebrate retina.  Prog Lipid Res. 1983;2279- 131Google ScholarCrossref
Gerster  H Review: antioxidant protection of the ageing macula.  Age Ageing. 1991;2060- 69Google ScholarCrossref
Young  RW Solar radiation and age-related macular degeneration.  Surv Ophthalmol. 1988;32252- 269Google ScholarCrossref
Beatty  SKoh  HPhil  MHenson  DBoulton  M The role of oxidative stress in the pathogenesis of age-related macular degeneration.  Surv Ophthalmol. 2000;45115- 134Google ScholarCrossref
Seddon  JMAjani  UASperduto  RD  et al.  Dietary carotenoids, vitamins A, C, and E and advanced age-related macular degeneration.  JAMA. 1994;2721413- 1420Google ScholarCrossref
Eye Disease Case-Control Study Group, Antioxidant status and neovascular age-related macular degeneration.  Arch Ophthalmol. 1993;111104- 109Google ScholarCrossref
Goldberg  JFlowerdew  GSmith  EBrody  JATso  MOM Factors associated with age-related macular degeneration: an analysis of data from the First National Health and Nutrition Examination Survey.  Am J Epidemiol. 1988;128700- 710Google Scholar
VandenLangenberg  GWMares-Perlman  JAKlein  RKlein  BEKBrady  WEPalta  M Associations between antioxidant and zinc intake and the 5-year incidence of early age-related maculopathy in the Beaver Dam Eye Study.  Am J Epidemiol. 1998;148204- 214Google ScholarCrossref
Christen  WGAjani  UAGlynn  RJ  et al.  A prospective cohort study of antioxidant vitamin supplement use and the risk of age-related maculopathy.  Am J Epidemiol. 1999;149476- 484Google ScholarCrossref
West  SVitale  SHallfrisch  J  et al.  Are antioxidants or supplements protective for age-related macular degeneration?  Arch Ophthalmol. 1994;112222- 227Google ScholarCrossref
Smith  WMitchell  PWebb  KLeeder  SR Dietary antioxidants and age-related maculopathy: the Blue Mountains Eye Study.  Ophthalmology. 1999;106761- 767Google ScholarCrossref
Seddon  JMHennekens  CH Vitamins, minerals and macular degeneration: promising but unproven hypotheses.  Arch Ophthalmol. 1994;112176- 179Google ScholarCrossref
Cho  EStampfer  MJSeddon  JM  et al.  Prospective study of zinc intake and the risk of age-related macular degeneration.  Ann Epidemiol. 2001;11328- 336Google ScholarCrossref
Newsome  DASwartz  MLeone  NCElston  RCMiller  E Oral zinc in macular degeneration.  Arch Ophthalmol. 1988;106192- 198Google ScholarCrossref
Teikari  JMLaatikainen  LVirtamo  J  et al.  Six-year supplementation with alpha tocopherol and beta-carotene and age-related maculopathy.  Acta Ophthalmol Scand. 1998;76224- 229Google ScholarCrossref
Stur  MTittl  MReitner  AMesinger  V Oral zinc and the second eye in age-related macular degeneration.  Invest Ophthalmol Vis Sci. 1996;371225- 1235Google Scholar
Sperduto  RDFerris  FL  IIIKurinij  N Editorial. Do we have a nutritional treatment for age-related cataract or macular degeneration?  Arch Ophthalmol. 1990;1081403- 1405Google ScholarCrossref
National Research Council, Recommended Dietary Allowances. Tenth Washington, DC National Academy Press1989;
The Age-Related Eye Disease Study Research Group, The Age-Related Eye Disease Study (AREDS): design implications: AREDS Report No. 1.  Control Clin Trials. 1999;20573- 600Google ScholarCrossref
Bressler  SBMaguire  MGBressler  NMFine  SLthe Macular Photocoagulation Study Group, Relationship of drusen and abnormalities of the retinal pigment epithelium to the prognosis of neovascular macular degeneration.  Arch Ophthalmol. 1990;1081442- 1447Google ScholarCrossref
The Age-Related Eye Disease Study Research Group, The Age-Related Eye Disease Study (AREDS) system for classifying age-related macular degeneration from stereoscopic color fundus photographs: AREDS Report No. 6.  Ophthalmology. In press.Google Scholar
McCarty  CALee  SELivingston  PMBissinella  MTaylor  HR Ocular exposure to UV-B in sunlight: the Melbourne visual impairment project model.  Bull World Health Organ. 1996;74353- 360Google Scholar
Mangione  CMLee  PPGutierrez  PRSpritzer  KBerry  SHays  RD Development of the 25-item National Eye Institute Visual Function Questionnaire.  Arch Ophthalmol. 2001;1191050- 1058Google ScholarCrossref
Klein  RKlein  BEKLinton  KLP Prevalence of age-related maculopathy: The Beaver Dam Eye Study.  Ophthalmology. 1992;99933- 943Google ScholarCrossref
Zhang  JYu  KF What's the relative risk?  JAMA. 1998;2801690- 1691Google ScholarCrossref
Lan  KKGLachin  JM Implementation of group sequential logrank tests in a maximum duration trial.  Biometrics. 1990;46759- 770Google ScholarCrossref
O'Brien  PCFleming  TR A multiple testing procedure for clinical trials.  Biometrics. 1979;35549- 556Google ScholarCrossref
Pocock  SJ Group sequential methods in the design and analysis of clinical trials.  Biometrika. 1977;64191- 199Google ScholarCrossref
Omenn  GSGoodman  GEThornquist  MD  et al.  Effects of a combination of beta carotene and vitamin A on lung cancer and cardiovascular disease.  N Engl J Med. 1996;3341150- 1155Google ScholarCrossref
The Alpha-Tocopherol, Beta Carotene Cancer Prevention Study Group, The effect of vitamin E and beta carotene on the incidence of lung cancer and other cancers in male smokers.  N Engl J Med. 1994;3301029- 1035Google ScholarCrossref
Alaimo  KMcDowell  MABriefel  RR  et al.  Dietary intake of vitamins, minerals, and fiber of persons ages 2 months and over in the United States: Third National Health and Nutrition Examination Survey, Phase 1, 1988-91.  Adv Data. 1994;2581- 28Google Scholar
World Health Organization, International Classification of Diseases, Ninth Revision(ICD-9).  Geneva, Switzerland World Health Organization1977;
Age-Related Eye Disease Study Research Group, A randomized, placebo-controlled clinical trial of high-dose supplementation with vitamins C and E and beta carotene for age-related cataract and vision loss: AREDS Report No. 9.  Arch Ophthalmol. 2001;1191439- 1452Google ScholarCrossref
Taylor  HRTikellis  GRobman  LDMcCarty  CAMcNeil  JJ Vitamin E supplementation and age-related maculopathy [ARVO abstract].  Invest Ophthalmol Vis Sci. 2001;42S311Abstract No. 1676.Google Scholar
National Center for Health Statistics, Vital Statistics of the United States, 1993, Preprint of Vol II, Mortality, Part A Section 6 Life Tables.  Hyattsville, Md National Center for Health Statistics1997;
Bone  RALandrum  JTTarsis  SL Preliminary identification of the human macular pigment.  Vision Res. 1985;251531- 1535Google ScholarCrossref
The Age-Related Eye Disease Study Research Group, Risk factors associated with age-related macular degeneration: a case-control study in the Age-Related Eye Disease Study: AREDS Report No 3.  Ophthalmology. 2000;1072224- 2232Google ScholarCrossref
Snodderly  DM Evidence for protection against age-related macular degeneration by carotenoids and antioxidant vitamins.  Am J Clin Nutr. 1995;621448S- 1461SGoogle Scholar
Clinical Sciences
October 2001

A Randomized, Placebo-Controlled, Clinical Trial of High-Dose Supplementation With Vitamins C and E, Beta Carotene, and Zinc for Age-Related Macular Degeneration and Vision Loss: AREDS Report No. 8

Age-Related Eye Disease Study Research Group
Author Affiliations

The AREDS investigators have no commercial or proprietary interest in the supplements used in this study.

Arch Ophthalmol. 2001;119(10):1417-1436. doi:10.1001/archopht.119.10.1417

Background  Observational and experimental data suggest that antioxidant and/or zinc supplements may delay progression of age-related macular degeneration(AMD) and vision loss.

Objective  To evaluate the effect of high-dose vitamins C and E, beta carotene, and zinc supplements on AMD progression and visual acuity.

Design  The Age-Related Eye Disease Study, an 11-center double-masked clinical trial, enrolled participants in an AMD trial if they had extensive small drusen, intermediate drusen, large drusen, noncentral geographic atrophy, or pigment abnormalities in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye. At least 1 eye had best-corrected visual acuity of 20/32 or better. Participants were randomly assigned to receive daily oral tablets containing:(1) antioxidants (vitamin C, 500 mg; vitamin E, 400 IU; and beta carotene, 15 mg); (2) zinc, 80 mg, as zinc oxide and copper, 2 mg, as cupric oxide;(3) antioxidants plus zinc; or (4) placebo.

Main Outcome Measures  (1) Photographic assessment of progression to or treatment for advanced AMD and (2) at least moderate visual acuity loss from baseline (≥15 letters). Primary analyses used repeated-measures logistic regression with a significance level of .01, unadjusted for covariates. Serum level measurements, medical histories, and mortality rates were used for safety monitoring.

Results  Average follow-up of the 3640 enrolled study participants, aged 55-80 years, was 6.3 years, with 2.4% lost to follow-up. Comparison with placebo demonstrated a statistically significant odds reduction for the development of advanced AMD with antioxidants plus zinc (odds ratio [OR], 0.72; 99% confidence interval [CI], 0.52-0.98). The ORs for zinc alone and antioxidants alone are 0.75 (99% CI, 0.55-1.03) and 0.80 (99% CI, 0.59-1.09), respectively. Participants with extensive small drusen, nonextensive intermediate size drusen, or pigment abnormalities had only a 1.3% 5-year probability of progression to advanced AMD. Odds reduction estimates increased when these 1063 participants were excluded (antioxidants plus zinc: OR, 0.66; 99% CI, 0.47-0.91; zinc: OR, 0.71; 99% CI, 0.52-0.99; antioxidants: OR, 0.76; 99% CI, 0.55-1.05). Both zinc and antioxidants plus zinc significantly reduced the odds of developing advanced AMD in this higher-risk group. The only statistically significant reduction in rates of at least moderate visual acuity loss occurred in persons assigned to receive antioxidants plus zinc (OR, 0.73; 99% CI, 0.54-0.99). No statistically significant serious adverse effect was associated with any of the formulations.

Conclusions  Persons older than 55 years should have dilated eye examinations to determine their risk of developing advanced AMD. Those with extensive intermediate size drusen, at least 1 large druse, noncentral geographic atrophy in 1 or both eyes, or advanced AMD or vision loss due to AMD in 1 eye, and without contraindications such as smoking, should consider taking a supplement of antioxidants plus zinc such as that used in this study.